104 related articles for article (PubMed ID: 35511742)
21. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
22. Midlife metabolic factors and prostate cancer risk in later life.
Dickerman BA; Torfadottir JE; Valdimarsdottir UA; Wilson KM; Steingrimsdottir L; Aspelund T; Batista JL; Fall K; Giovannucci E; Sigurdardottir LG; Tryggvadottir L; Gudnason V; Markt SC; Mucci LA
Int J Cancer; 2018 Mar; 142(6):1166-1173. PubMed ID: 29114858
[TBL] [Abstract][Full Text] [Related]
23. Receiver operating characteristics of the prostate specific antigen test in an unselected population.
McLernon DJ; Donnan PT; Gray M; Weller D; Sullivan F
J Med Screen; 2006; 13(2):102-7. PubMed ID: 16792835
[TBL] [Abstract][Full Text] [Related]
24. Blood pressure and bladder cancer risk in men by use of survival analysis and in interaction with NAT2 genotype, and by Mendelian randomization analysis.
Teleka S; Hindy G; Drake I; Poveda A; Melander O; Liedberg F; Orho-Melander M; Stocks T
PLoS One; 2020; 15(11):e0241711. PubMed ID: 33237904
[TBL] [Abstract][Full Text] [Related]
25. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
26. Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study.
Aly M; Clements M; Weibull CE; Nordström T; Näslund E; Adolfsson J; Grönberg H
Eur Urol Focus; 2019 Sep; 5(5):842-848. PubMed ID: 29433987
[TBL] [Abstract][Full Text] [Related]
27. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.
Chamie K; DeVere White RW; Lee D; Ok JH; Ellison LM
Cancer; 2008 Nov; 113(9):2464-70. PubMed ID: 18666213
[TBL] [Abstract][Full Text] [Related]
28. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes.
Yang WY; Melgarejo JD; Thijs L; Zhang ZY; Boggia J; Wei FF; Hansen TW; Asayama K; Ohkubo T; Jeppesen J; Dolan E; Stolarz-Skrzypek K; Malyutina S; Casiglia E; Lind L; Filipovský J; Maestre GE; Li Y; Wang JG; Imai Y; Kawecka-Jaszcz K; Sandoya E; Narkiewicz K; O'Brien E; Verhamme P; Staessen JA;
JAMA; 2019 Aug; 322(5):409-420. PubMed ID: 31386134
[TBL] [Abstract][Full Text] [Related]
29. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
30. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
[TBL] [Abstract][Full Text] [Related]
31. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality.
Bitterman DS; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2021 Aug; 127(15):2623-2630. PubMed ID: 33823065
[TBL] [Abstract][Full Text] [Related]
33. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
34. Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation.
Kaneko H; Yano Y; Itoh H; Morita K; Kiriyama H; Kamon T; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Node K; Carey RM; Lima JAC; Oparil S; Yasunaga H; Komuro I
Circulation; 2021 Jun; 143(23):2244-2253. PubMed ID: 33886370
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
36. Educational level and first-time PSA testing in general practice.
Lerhmann-Lerche CS; Larsen SB; Andersen I; Thygesen LC; Kaae Andersen K; Duun-Henriksen AK; Johansen C; Røder MA; Brasso K; Dalton SO
Scand J Urol; 2019 Oct; 53(5):275-281. PubMed ID: 31663414
[No Abstract] [Full Text] [Related]
37. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
38. Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).
Nielsen OW; Sajadieh A; Sabbah M; Greve AM; Olsen MH; Boman K; Nienaber CA; Kesäniemi YA; Pedersen TR; Willenheimer R; Wachtell K
Circulation; 2016 Aug; 134(6):455-68. PubMed ID: 27486164
[TBL] [Abstract][Full Text] [Related]
39. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer.
Fitzpatrick AL; Daling JR; Furberg CD; Kronmal RA; Weissfeld JL
Ann Epidemiol; 2001 Nov; 11(8):534-42. PubMed ID: 11709272
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
